Table 2 Side effect profiles of PCSK9 mAbs.
From: Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives
Side effect profiles | Description | ||
|---|---|---|---|
| Â | Symptoms | Occurence | |
| Â | Â | Alirocumab vs placebo (%) | Evolocumab vs placebo (%) |
Neurocognitive adverse effects | Amnesia mental impairment | 0.8 vs 0.7 | No |
| Â | Injection site reactions | 7.2 vs 5.1 | 5.7 vs 5.0 |
| Â | Nasopharyngitis | 11.3 vs 11.1 | 10.5 vs 9.6 |
| Â | Influenza | 5.7 vs 4.6 | 7.5 vs 6.3 |
| Â | Urinary tract infections | 4.8 vs 4.6 | 4.5 vs 3.6 |
| Â | Cough | 2.5 vs 2.3 | 4.5 vs 3.6 |
| Â | Myalgia | 4.2 vs 3.4 | 4.0 vs 3.0 |
| Â | Sinusitis | 3.0 vs 2.7 | 4.2 vs 3.0 |
Other adverse events in clinical trials of PCSK9 mAbs | Musculoskeletal pain | 2.1 vs 1.6 | 3.3 vs 3.0 |
| Â | Bronchitis | 4.3 vs 3.8 | Â |
| Â | Diarrhea | 4.7 vs 4.4 | 3.0 vs 2.6 |
| Â | Upper respiratory tract infections | 3.1 vs 2.4 | 9.3 vs 6.3 |
| Â | Back pain | Â | Â |
| Â | Headache | Â | 6.2 vs 5.6 |
| Â | Dizziness | Â | 4.0 vs 3.6 |
| Â | Hypertension | Â | 3.7 vs 2.6 |
| Â | Gastroenteritis | Â | 3.2 vs 2.3 3.0 vs 2.0 |
